Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints

被引:75
作者
Kesselheim, Aaron S. [1 ,2 ]
Mello, Michelle M. [3 ]
Studdert, David M. [4 ,5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
[4] Univ Melbourne, Sch Law, Melbourne, Vic, Australia
[5] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic, Australia
基金
澳大利亚研究理事会;
关键词
PROMOTION; FRAUD; CARE;
D O I
10.1371/journal.pmed.1000431
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite regulatory restrictions, off-label marketing of pharmaceutical products has been common in the US. However, the scope of off-label marketing remains poorly characterized. We developed a typology for the strategies and practices that constitute off-label marketing. Methods and Findings: We obtained unsealed whistleblower complaints against pharmaceutical companies filed in US federal fraud cases that contained allegations of off-label marketing (January 1996-October 2010) and conducted structured reviews of them. We coded and analyzed the strategic goals of each off-label marketing scheme and the practices used to achieve those goals, as reported by the whistleblowers. We identified 41 complaints arising from 18 unique cases for our analytic sample (leading to US$7.9 billion in recoveries). The off-label marketing schemes described in the complaints had three non-mutually exclusive goals: expansions to unapproved diseases (35/41, 85%), unapproved disease subtypes (22/41, 54%), and unapproved drug doses (14/41, 34%). Manufacturers were alleged to have pursued these goals using four non-mutually exclusive types of marketing practices: prescriber-related (41/41, 100%), business-related (37/41, 90%), payer-related (23/41, 56%), and consumer-related (18/41, 44%). Prescriber-related practices, the centerpiece of company strategies, included self-serving presentations of the literature (31/41, 76%), free samples (8/41, 20%), direct financial incentives to physicians (35/41, 85%), and teaching (22/41, 54%) and research activities (8/41, 20%). Conclusions: Off-label marketing practices appear to extend to many areas of the health care system. Unfortunately, the most common alleged off-label marketing practices also appear to be the most difficult to control through external regulatory approaches.
引用
收藏
页数:9
相关论文
共 32 条
[1]  
Almashat S., 2010, Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 to 2010
[2]  
[Anonymous], NY TIMES
[3]  
CONSTAS MA, 1992, AM EDUC RES J, V29, P253, DOI 10.2307/1163368
[4]  
*DEP JUST, 2010, NOV VACC DIAGN PAY M
[5]  
*DEP JUST, 2010, 2 JOHNS JOHNS SUBS P
[6]  
*DEP JUST, 2010, ALL AGR PLEAD GUILT
[7]  
*DEP JUST, 2010, NOV PHARM CORP PAY M
[8]  
*DEP JUST, 2010, DRUG MAK FOR PLEADS
[9]  
*DEP JUST, 2010, PHARM GIANT ASTRAZEN
[10]   Toward More Uniform Conflict Disclosures - The Updated ICMJE Conflict of Interest Reporting Form [J].
Drazen, Jeffrey M. ;
de Leeuw, Peter W. ;
Laine, Christine ;
Mulrow, Cynthia ;
DeAngelis, Catherine D. ;
Frizelle, Frank A. ;
Godlee, Fiona ;
Haug, Charlotte ;
Hebert, Paul C. ;
James, Astrid ;
Kotzin, Sheldon ;
Marusic, Ana ;
Reyes, Humberto ;
Rosenberg, Jacob ;
Sahni, Peush ;
Van Der Weyden, Martin B. ;
Zhaori, Getu .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02) :188-189